Ovid Therapeutics (OVID) Sets New 12-Month Low at $1.66

Ovid Therapeutics Inc (NASDAQ:OVID) shares reached a new 52-week low on Monday . The stock traded as low as $1.66 and last traded at $1.74, with a volume of 3804 shares traded. The stock had previously closed at $1.83.

Several analysts recently issued reports on OVID shares. Zacks Investment Research upgraded Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Saturday, March 9th. Piper Jaffray Companies dropped their target price on Ovid Therapeutics to $14.00 and set an “overweight” rating on the stock in a report on Sunday, March 10th. JMP Securities dropped their target price on Ovid Therapeutics from $26.00 to $11.00 and set an “outperform” rating on the stock in a report on Friday, March 8th. LADENBURG THALM/SH SH set a $27.00 target price on Ovid Therapeutics and gave the stock a “buy” rating in a report on Friday, March 8th. Finally, Cantor Fitzgerald set a $10.00 target price on Ovid Therapeutics and gave the stock a “buy” rating in a report on Monday, December 17th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $12.80.

The firm has a market capitalization of $71.11 million, a PE ratio of -0.87 and a beta of 1.96.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities research analysts forecast that Ovid Therapeutics Inc will post -1.89 earnings per share for the current year.

In other Ovid Therapeutics news, CEO Jeremy M. Levin acquired 75,000 shares of the company’s stock in a transaction on Friday, February 22nd. The shares were purchased at an average price of $2.00 per share, for a total transaction of $150,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 43.90% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its stake in Ovid Therapeutics by 47.2% in the fourth quarter. Rhumbline Advisers now owns 16,551 shares of the company’s stock valued at $40,000 after buying an additional 5,310 shares during the period. Geode Capital Management LLC raised its stake in Ovid Therapeutics by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock valued at $231,000 after buying an additional 6,391 shares during the period. Dimensional Fund Advisors LP raised its stake in Ovid Therapeutics by 11.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 87,257 shares of the company’s stock valued at $211,000 after buying an additional 8,995 shares during the period. SG Americas Securities LLC bought a new stake in Ovid Therapeutics in the fourth quarter valued at approximately $46,000. Finally, JPMorgan Chase & Co. raised its stake in Ovid Therapeutics by 136.9% in the third quarter. JPMorgan Chase & Co. now owns 54,832 shares of the company’s stock valued at $311,000 after buying an additional 31,687 shares during the period. Hedge funds and other institutional investors own 17.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://transcriptdaily.com/2019/04/15/ovid-therapeutics-ovid-sets-new-12-month-low-at-1-66.html.

About Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Read More: How mutual funds make money

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.